Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Hjorthaug

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Ugeskrift for Laeger|July 27, 2010
[Pheochromocytoma presenting as ischaemic gangrene of lower limbs]Kristina Galsgaard, Ole Hilberg, Karin Hjorthaug
EJNMMI Research|September 23, 2016
Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapyJoan Fledelius, Azza Khalil, Karin Hjorthaug, et al.
Journal of Medical Imaging and Radiation Oncology|December 19, 2015
Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC)Joan Fledelius, Azza Ahmed Khalil, Karin Hjorthaug, et al.
American Journal of Nuclear Medicine and Molecular Imaging|March 14, 2018
Assessment of very early response evaluation with <sup>18</sup>F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methodsJoan Fledelius, Anne Winther-Larsen, Azza A Khalil, et al.
European Journal of Hybrid Imaging|August 24, 2022
Early acquisition of [<sup>18</sup>F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe-and slightly better!Mette Louise Gram Kjærulff, André H Dias, Peter Iversen, et al.
EJNMMI Research|December 19, 2023
[<sup>18</sup>F]FDOPA PET/CT is superior to [<sup>68</sup>Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytomaPeter Iversen, Stine Kramer, Andreas Ebbehoj, et al.
The Journal of Clinical Endocrinology and Metabolism|October 29, 2024
Positron Emission Tomography Imaging of Pheochromocytoma and Paraganglioma-18F-FDOPA vs Somatostatin AnaloguesAndreas Ebbehoj, Peter Iversen, Stine Kramer, et al.
EJNMMI Research|March 29, 2022
Clinical feasibility and impact of data-driven respiratory motion compensation studied in 200 whole-body <sup>18</sup>F-FDG PET/CT scansAndré H Dias, Paul Schleyer, Mikkel H Vendelbo, et al.
British Journal of Cancer|July 7, 2017
Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patientsAnne Winther-Larsen, Christina Demuth, Joan Fledelius, et al.
Tomography (Ann Arbor, Mich.)|July 27, 2022
Assessment of Correlation between Dual-Energy Ct (De-Ct)-Derived Iodine Concentration and Local Flourodeoxyglucose (Fdg) Uptake in Patients with Primary Non-Small-Cell Lung CancerMichael Brun Andersen, Aska Drljevic-Nielsen, Jesper Thygesen, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Ugeskrift for Laeger|July 27, 2010
[Pheochromocytoma presenting as ischaemic gangrene of lower limbs]Kristina Galsgaard, Ole Hilberg, Karin Hjorthaug
EJNMMI Research|September 23, 2016
Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapyJoan Fledelius, Azza Khalil, Karin Hjorthaug, et al.
Journal of Medical Imaging and Radiation Oncology|December 19, 2015
Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC)Joan Fledelius, Azza Ahmed Khalil, Karin Hjorthaug, et al.
American Journal of Nuclear Medicine and Molecular Imaging|March 14, 2018
Assessment of very early response evaluation with <sup>18</sup>F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methodsJoan Fledelius, Anne Winther-Larsen, Azza A Khalil, et al.
European Journal of Hybrid Imaging|August 24, 2022
Early acquisition of [<sup>18</sup>F]FDOPA PET/CT imaging in patients with recurrent or residual medullary thyroid cancer is safe-and slightly better!Mette Louise Gram Kjærulff, André H Dias, Peter Iversen, et al.
EJNMMI Research|December 19, 2023
[<sup>18</sup>F]FDOPA PET/CT is superior to [<sup>68</sup>Ga]DOTATOC PET/CT in diagnostic imaging of pheochromocytomaPeter Iversen, Stine Kramer, Andreas Ebbehoj, et al.
The Journal of Clinical Endocrinology and Metabolism|October 29, 2024
Positron Emission Tomography Imaging of Pheochromocytoma and Paraganglioma-18F-FDOPA vs Somatostatin AnaloguesAndreas Ebbehoj, Peter Iversen, Stine Kramer, et al.
EJNMMI Research|March 29, 2022
Clinical feasibility and impact of data-driven respiratory motion compensation studied in 200 whole-body <sup>18</sup>F-FDG PET/CT scansAndré H Dias, Paul Schleyer, Mikkel H Vendelbo, et al.
British Journal of Cancer|July 7, 2017
Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patientsAnne Winther-Larsen, Christina Demuth, Joan Fledelius, et al.
Tomography (Ann Arbor, Mich.)|July 27, 2022
Assessment of Correlation between Dual-Energy Ct (De-Ct)-Derived Iodine Concentration and Local Flourodeoxyglucose (Fdg) Uptake in Patients with Primary Non-Small-Cell Lung CancerMichael Brun Andersen, Aska Drljevic-Nielsen, Jesper Thygesen, et al.
Pageof 3